Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study)
OBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43±9 y...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Cardiologia (SBC)
2000-03-01
|
| Series: | Arquivos Brasileiros de Cardiologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2000000300005 |
| _version_ | 1818118363470102528 |
|---|---|
| author | Paulo Roberto Chizzola Humberto Felício Gonçalves Freitas Márcia Azevedo Caldas Joicely Melo da Costa Cláudio Meneghetti Norma Vasconcelos Saldanha Marinho Alfredo José Mansur José Antonio Franchini Ramires Edimar Alcides Bocchi |
| author_facet | Paulo Roberto Chizzola Humberto Felício Gonçalves Freitas Márcia Azevedo Caldas Joicely Melo da Costa Cláudio Meneghetti Norma Vasconcelos Saldanha Marinho Alfredo José Mansur José Antonio Franchini Ramires Edimar Alcides Bocchi |
| author_sort | Paulo Roberto Chizzola |
| collection | DOAJ |
| description | OBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43±9 years), and their left ventricular ejection fraction varied from 8% to 35%. Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients. The initial dose of carvedilol was 12.5 mg, which was increased weekly until it reached 75 mg/day, according to the patient's tolerance. Clinical assessment, electrocardiogram, echocardiogram, and radionuclide ventriculography were performed in the pretreatment phase, being repeated after 2 and 6 months of medication use. RESULTS: A reduction in heart rate (p=0.016) as well as an increase in left ventricular shortening fraction (p=0.02) and in left ventricular ejection fraction (p=0.017) occurred in the group using carvedilol as compared with that using placebo. CONCLUSION: Carvedilol added to the usual therapy for heart failure resulted in better heart function. |
| first_indexed | 2024-12-11T04:53:07Z |
| format | Article |
| id | doaj.art-096e47ad5e24449fa2cdbf9230ce3233 |
| institution | Directory Open Access Journal |
| issn | 0066-782X 1678-4170 |
| language | English |
| last_indexed | 2024-12-11T04:53:07Z |
| publishDate | 2000-03-01 |
| publisher | Sociedade Brasileira de Cardiologia (SBC) |
| record_format | Article |
| series | Arquivos Brasileiros de Cardiologia |
| spelling | doaj.art-096e47ad5e24449fa2cdbf9230ce32332022-12-22T01:20:19ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia0066-782X1678-41702000-03-0174323824210.1590/S0066-782X2000000300005Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study)Paulo Roberto ChizzolaHumberto Felício Gonçalves FreitasMárcia Azevedo CaldasJoicely Melo da CostaCláudio MeneghettiNorma Vasconcelos Saldanha MarinhoAlfredo José MansurJosé Antonio Franchini RamiresEdimar Alcides BocchiOBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43±9 years), and their left ventricular ejection fraction varied from 8% to 35%. Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients. The initial dose of carvedilol was 12.5 mg, which was increased weekly until it reached 75 mg/day, according to the patient's tolerance. Clinical assessment, electrocardiogram, echocardiogram, and radionuclide ventriculography were performed in the pretreatment phase, being repeated after 2 and 6 months of medication use. RESULTS: A reduction in heart rate (p=0.016) as well as an increase in left ventricular shortening fraction (p=0.02) and in left ventricular ejection fraction (p=0.017) occurred in the group using carvedilol as compared with that using placebo. CONCLUSION: Carvedilol added to the usual therapy for heart failure resulted in better heart function.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2000000300005heart failurebeta-blockerdilated cardiomyopathy |
| spellingShingle | Paulo Roberto Chizzola Humberto Felício Gonçalves Freitas Márcia Azevedo Caldas Joicely Melo da Costa Cláudio Meneghetti Norma Vasconcelos Saldanha Marinho Alfredo José Mansur José Antonio Franchini Ramires Edimar Alcides Bocchi Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) Arquivos Brasileiros de Cardiologia heart failure beta-blocker dilated cardiomyopathy |
| title | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) |
| title_full | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) |
| title_fullStr | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) |
| title_full_unstemmed | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) |
| title_short | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study) |
| title_sort | effects of carvedilol in heart failure due to dilated cardiomyopathy results of a double blind randomized placebo controlled study caribe study |
| topic | heart failure beta-blocker dilated cardiomyopathy |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2000000300005 |
| work_keys_str_mv | AT paulorobertochizzola effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT humbertofeliciogoncalvesfreitas effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT marciaazevedocaldas effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT joicelymelodacosta effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT claudiomeneghetti effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT normavasconcelossaldanhamarinho effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT alfredojosemansur effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT joseantoniofranchiniramires effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy AT edimaralcidesbocchi effectsofcarvedilolinheartfailureduetodilatedcardiomyopathyresultsofadoubleblindrandomizedplacebocontrolledstudycaribestudy |